全文获取类型
收费全文 | 24104篇 |
免费 | 6579篇 |
国内免费 | 87篇 |
专业分类
耳鼻咽喉 | 381篇 |
儿科学 | 658篇 |
妇产科学 | 653篇 |
基础医学 | 1248篇 |
口腔科学 | 1473篇 |
临床医学 | 7095篇 |
内科学 | 5094篇 |
皮肤病学 | 641篇 |
神经病学 | 2997篇 |
特种医学 | 702篇 |
外科学 | 3012篇 |
综合类 | 104篇 |
一般理论 | 16篇 |
预防医学 | 3452篇 |
眼科学 | 430篇 |
药学 | 831篇 |
中国医学 | 13篇 |
肿瘤学 | 1970篇 |
出版年
2023年 | 1369篇 |
2022年 | 334篇 |
2021年 | 799篇 |
2020年 | 1293篇 |
2019年 | 677篇 |
2018年 | 1696篇 |
2017年 | 1811篇 |
2016年 | 1837篇 |
2015年 | 1861篇 |
2014年 | 2144篇 |
2013年 | 2269篇 |
2012年 | 1272篇 |
2011年 | 1355篇 |
2010年 | 1401篇 |
2009年 | 1706篇 |
2008年 | 1034篇 |
2007年 | 843篇 |
2006年 | 943篇 |
2005年 | 720篇 |
2004年 | 563篇 |
2003年 | 587篇 |
2002年 | 494篇 |
2001年 | 354篇 |
2000年 | 186篇 |
1999年 | 290篇 |
1998年 | 329篇 |
1997年 | 321篇 |
1996年 | 335篇 |
1995年 | 283篇 |
1994年 | 204篇 |
1993年 | 179篇 |
1992年 | 148篇 |
1991年 | 113篇 |
1990年 | 104篇 |
1989年 | 123篇 |
1988年 | 101篇 |
1987年 | 72篇 |
1986年 | 72篇 |
1985年 | 59篇 |
1984年 | 48篇 |
1983年 | 45篇 |
1982年 | 41篇 |
1981年 | 39篇 |
1980年 | 29篇 |
1979年 | 35篇 |
1978年 | 32篇 |
1977年 | 24篇 |
1974年 | 27篇 |
1973年 | 18篇 |
1971年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
2.
3.
4.
Biniam Kidane MD MSc Ian J. Gerard MD PhD Jonathan Spicer MD PhD Julian O. Kim MD MSc BEng Pierre O. Fiset MD PhD Paul Wawryko MD Matthew J. Cecchini MD PhD Richard Inculet MD Bassam Abdulkarim MD PhD Dalilah Fortin MD Mehdi Qiabi MD MSc Gefei Qing MD Stephanie Enns BSc Bashir Bashir MBBS James Tankel MD Elliot Wakeam MD Andrew Warner MSc Neil Kopek MD Brian P. Yaremko MD MSc PEng George B. Rodrigues MD PhD Joanna M. Laba MD Melody Qu MD MPH Richard A. Malthaner MD MSc David A. Palma MD PhD 《Cancer》2023,129(18):2798-2807
Background
During coronavirus disease 2019 (COVID-19)–related operating room closures, some multidisciplinary thoracic oncology teams adopted a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to surgery, an approach called SABR-BRIDGE. This study presents the preliminary surgical and pathological results.Methods
Eligible participants from four institutions (three in Canada and one in the United States) had early-stage presumed or biopsy-proven lung malignancy that would normally be surgically resected. SABR was delivered using standard institutional guidelines, with surgery >3 months following SABR with standardized pathologic assessment. Pathological complete response (pCR) was defined as absence of viable cancer. Major pathologic response (MPR) was defined as ≤10% viable tissue.Results
Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3–4 (26%, n = 19), and 50/55 Gy/5 (22%, n = 16). SABR was well-tolerated, with one grade 5 toxicity (death 10 days after SABR with COVID-19) and five grade 2–3 toxicities. Following SABR, 26 patients underwent resection thus far (13 pending surgery). Median time-to-surgery was 4.5 months post-SABR (range, 2–17.5 months). Surgery was reported as being more difficult because of SABR in 38% (n = 10) of cases. Thirteen patients (50%) had pCR and 19 (73%) had MPR. Rates of pCR trended higher in patients operated on at earlier time points (75% if within 3 months, 50% if 3–6 months, and 33% if ≥6 months; p = .069). In the exploratory best-case scenario analysis, pCR rate does not exceed 82%.Conclusions
The SABR-BRIDGE approach allowed for delivery of treatment during a period of operating room closure and was well-tolerated. Even in the best-case scenario, pCR rate does not exceed 82%. 相似文献5.
6.
7.
8.
9.